

LETTERS

The authors respond to “Treatment of subclinical hypothyroidism in pregnant women”

We thank Dr. Romney¹ for his response to our article.²

The guideline from the American Thyroid Association has two separate recommendations for women who test positive for thyroid peroxidase antibodies.³ The recommendations apply to those with a thyroid-stimulating hormone (TSH) level between 2.5 mIU/L and the pregnancy-specific upper limit of normal (typically 2.5–3.0 mIU/L), and those who have a TSH level greater than the reference range. There is a strong recommendation to treat those above the reference range and a weak recommendation to treat those with a level of 2.5–3.0 mIU/L. Our statement in point four combined both of these groups.

Siobhan Deshauer MD

Internal medicine resident, McMaster University, Hamilton, Ont.

Ahraaz Wyne MD

Assistant professor, Division of General Internal Medicine, Department of Medicine, McMaster University, Hamilton, Ont.

■ Cite as: *CMAJ* 2018 April 30;190:E546.
doi: 10.1503/cmaj.69226

References

1. Romney JS. Treatment of subclinical hypothyroidism in pregnant women [letter]. *CMAJ* 2018; 190:E545.
2. Deshauer S, Wyne A. Subclinical hypothyroidism in pregnancy. *CMAJ* 2017;189:E941.
3. Alexander EK, Pearce EN, Brent GA, et al. 2017 guidelines of the American Thyroid Association for the diagnosis and management of thyroid disease during pregnancy and the postpartum. *Thyroid* 2017;27:315-89.

Competing interests: None declared.